Next Article in Journal
Liquid Biopsy of Non-Plasma Body Fluids in Non-Small Cell Lung Cancer: Look Closer to the Tumor!
Next Article in Special Issue
Hearing Loss in Alzheimer’s Disease Is Associated with Altered Serum Lipidomic Biomarker Profiles
Previous Article in Journal
Quick, Coordinated and Authentic Reprogramming of Ribosome Biogenesis during iPSC Reprogramming
Previous Article in Special Issue
Proteomic Profiling of Extracellular Vesicles Derived from Cerebrospinal Fluid of Alzheimer’s Disease Patients: A Pilot Study
Open AccessReview

Extracellular Vesicles in Alzheimer’s and Parkinson’s Disease: Small Entities with Large Consequences

1
VIB Center for Inflammation Research, VIB, 9052 Ghent, Belgium
2
Department of Biomedical Molecular Biology, Ghent University, 9000 Ghent, Belgium
3
Department of Neurology, Ghent University Hospital, 9000 Ghent, Belgium
*
Author to whom correspondence should be addressed.
Cells 2020, 9(11), 2485; https://doi.org/10.3390/cells9112485
Received: 17 October 2020 / Revised: 9 November 2020 / Accepted: 10 November 2020 / Published: 15 November 2020
Alzheimer’s disease (AD) and Parkinson’s disease (PD) are incurable, devastating neurodegenerative disorders characterized by the formation and spreading of protein aggregates throughout the brain. Although the exact spreading mechanism is not completely understood, extracellular vesicles (EVs) have been proposed as potential contributors. Indeed, EVs have emerged as potential carriers of disease-associated proteins and are therefore thought to play an important role in disease progression, although some beneficial functions have also been attributed to them. EVs can be isolated from a variety of sources, including biofluids, and the analysis of their content can provide a snapshot of ongoing pathological changes in the brain. This underlines their potential as biomarker candidates which is of specific relevance in AD and PD where symptoms only arise after considerable and irreversible neuronal damage has already occurred. In this review, we discuss the known beneficial and detrimental functions of EVs in AD and PD and we highlight their promising potential to be used as biomarkers in both diseases. View Full-Text
Keywords: extracellular vesicles; Alzheimer’s disease; Parkinson’s disease; biomarkers extracellular vesicles; Alzheimer’s disease; Parkinson’s disease; biomarkers
Show Figures

Figure 1

MDPI and ACS Style

Vandendriessche, C.; Bruggeman, A.; Van Cauwenberghe, C.; Vandenbroucke, R.E. Extracellular Vesicles in Alzheimer’s and Parkinson’s Disease: Small Entities with Large Consequences. Cells 2020, 9, 2485. https://doi.org/10.3390/cells9112485

AMA Style

Vandendriessche C, Bruggeman A, Van Cauwenberghe C, Vandenbroucke RE. Extracellular Vesicles in Alzheimer’s and Parkinson’s Disease: Small Entities with Large Consequences. Cells. 2020; 9(11):2485. https://doi.org/10.3390/cells9112485

Chicago/Turabian Style

Vandendriessche, Charysse; Bruggeman, Arnout; Van Cauwenberghe, Caroline; Vandenbroucke, Roosmarijn E. 2020. "Extracellular Vesicles in Alzheimer’s and Parkinson’s Disease: Small Entities with Large Consequences" Cells 9, no. 11: 2485. https://doi.org/10.3390/cells9112485

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop